Financings in Brief: Advanced Technology Laboratories
This article was originally published in The Gray Sheet
Executive SummaryAdvanced Technology Laboratories: Firm's board of directors approves the repurchase of up to 1 mil. shares of common stock in the company "from time to time in the open market, subject to certain conditions and limitations"...
You may also be interested in...
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.